Takeda, Cipla, Eisai and more—FiercePharmaAsia by Angus Liu Friday, July 19, 2019 Takeda sells €1.5 billion European drugs; top Indian drugmakers expand in China; Eisai moves closer to a quick Alzheimer’s blood test.
Indoco plant punished with warning letter by Eric Palmer Monday, July 15, 2019 Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.
Takeda-Shire, Nektar, Daiichi and more—FiercePharmaAsia by Angus Liu Friday, April 27, 2018 Takeda and Shire struck a buyout deal worth $64B; Nektar and Takeda teamed up for a combo cancer trial; and more.
Indoco Remedies cited by U.K. drug regulators by Joseph Keenan Wednesday, April 25, 2018 Indian drugmaker Indoco Remedies was cited by U.K. drug regulators for a number of issues at its manufacturing facility in Goa.
Indoco injectables plant smacked with FDA warning letter by Eric Palmer Wednesday, April 5, 2017 The FDA has nailed India's Indoco with a warning letter for a sterile and solid dose plant in Goa because of its concerns over an injected drug.
India's Indoco acknowledges Form 483 by Eric Palmer Tuesday, September 13, 2016 Indoco Remedies is the latest Indian drugmaker to run into issues with the FDA, having received a Form 483 with a half-dozen observations during a preapproval plant inspection.
